A Review of Novel Combinations of Colistin and Lipopeptide or Glycopeptide Antibiotics for the Treatment of Multidrug-Resistant Acinetobacter baumannii.

摘要: As antibiotic resistance continues to increase among Gram-negative organisms such as Acinetobacter baumannii there is a growing need for novel therapies overcome these mechanisms. Antibiotics active against multidrug-resistant A. (MDRAB) are few, and agents in development primarily other organisms. The combinations of colistin antimicrobials glycopeptides lipopeptides unique potential treatment modalities MDRAB. For both vitro data have demonstrated significant synergy, resulting rapid bactericidal activity time-kill curves. Several invertebrate vivo models also increased survival compared alone. Currently, very little clinical focused on using infections caused exclusively by Gram-negatives. combination vancomycin has been studied with conflicting results regarding improved outcomes risk nephrotoxicity. Although proved promising, further investigation required provide necessary support the use combinations. objective this review summarize literature currently available or baumannii, particular